ACUR · Acura Pharmaceuticals, Inc.

Summary

Acura Pharmaceuticals, Inc. received $100,000 loans from Abuse Deterrent Pharma, LLC on February 6, 2026, February 13, 2026, and March 9, 2026, increasing the principal balance under the November 10, 2022 Amended Consolidated and Restated Secured Promissory Note to $9,894,279 with accrued interest of approximately $1,040,000 as of February 28, 2026. The funding supports day-to-day operations amid warnings of potential operational scale-back or bankruptcy without additional financing by end of March 2026.

Key takeaways

• Loans of $100,000 received on 2/6/2026, 2/13/2026, and 3/9/2026 from Abuse Deterrent Pharma, LLC
• Note principal balance $9,894,279; accrued interest ~$1,040,000 as of 2/28/2026
• Interest rate 5.25%; overdue amounts at 7.5%
• AD Pharma owns ~65% of outstanding common stock as of 2/28/2026
• Mr. Schutte owns ~13% directly and controls AD Pharma
• Without additional financing by end March 2026, may furlough/lay-off employees or seek bankruptcy